SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.
(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE

- RESULTS OF RIGHTS CUM WARRANTS ISSUE

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below) and the Offer Information Statement (as defined below).

1. INTRODUCTION

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", together with its subsidiaries, collectively, the "**Group**") refers to the Company's announcements dated 30 October 2025, 13 February 2026, 22 April 2026, 12 May 2026, 20 May 2026, 2 June 2026 and 4 June 2026 (collectively, the "**Announcements**") and the Offer Information Statement dated 2 June 2026 ("**Offer Information Statement**") in relation to, *inter alia*, the renounceable non-underwritten Rights cum Warrants Issue to be undertaken by the Company.

2. RESULTS OF RIGHTS CUM WARRANTS ISSUE

2.1 Level of Subscription

The Board wishes to announce that, as at the Closing Date on 18 June 2026, the Company received valid acceptances and excess applications for a total of 589,932,505 Rights Shares with 589,932,505 Warrants, representing approximately 119.76% of the total number of 492,597,856 Rights Shares with 492,597,856 Warrants available for subscription under the Rights cum Warrants Issue. The Board extends its appreciation to all Shareholders for the support shown for the Rights cum Warrants Issue.

Details of the valid acceptances and excess applications for the Rights Shares with Warrants are as follows:

	Number of Rights Shares with Warrants	As a percentage of the total number of Rights Shares with Warrants available for subscription under the Rights cum Warrants Issue
Valid acceptances	400,983,508 Rights Shares with 400,983,508 Warrants [(1)]	81.40%
Valid excess applications	188,948,997 Rights Shares with 188,948,997 Warrants [(1)]	38.36%
Total	589,932,505 Rights Shares with 589,932,505 Warrants [(1)]	119.76%

Notes:

(1) This includes the valid acceptances and valid excess applications for the Rights Shares with Warrants by the Undertaking Shareholders, pursuant to the respective Undertaking Shareholders' Irrevocable Undertakings, comprising:

(a) An aggregate of 161,418,847 Rights Shares with 161,418,847 Warrants by the Berjaya Undertaking Shareholders, being Espeetex Sdn. Bhd., Berjaya Leisure (Cayman) Ltd and Bizurai Bijak (M) Sdn Bhd;

(b) An aggregate of 20,401,274 Rights Shares with 20,401,274 Warrants and 16,129,032 Excess Rights Shares with 16,129,032 Warrants by PHEIM, comprising PHEIM Asset Management (Asia) Pte Ltd, PHEIM Asset Management Sdn. Bhd. and PHEIM Islamic Asset Management Sdn. Bhd., collectively. For avoidance of doubt, PHEIM has subscribed and paid (and/or procured their respective associated companies and managed funds to subscribe and pay) for such number of Excess Rights Shares with Warrants amounting to an aggregate additional subscription amount of S$500,000;

(c) 59,890,400 Rights Shares with 59,890,400 Warrants and 20,135,180 Excess Rights Shares with 20,135,180 Warrants by Caterine Limited;

(d) 44,209,027 Rights Shares with 44,209,027 Warrants and 20,135,181 Excess Rights Shares with 20,135,181 Warrants by Crescendas Land Corporation Pte. Ltd.; and

(e) 26,300,000 Rights Shares with 26,300,000 Warrants by Dr Djeng Shih Kien ("**Dr Djeng**"), 5,650,000 Rights Shares with 5,650,000 Warrants by his spouse, Dr Ko Siew Lan, and 8,407,084 Rights Shares with 8,407,084 Warrants by Orthodontic & Dental Supplies Pte Ltd ("**ODS**"). Dr Djeng is deemed to have an interest in all the 5,650,000 Rights Shares with 5,650,000 Warrants held by his spouse, Dr Ko Siew Lan, and 8,407,084 Rights Shares with 8,407,084 Warrants held by ODS, under Section 7 of the Companies Act and Section 4 of the Securities and Futures Act 2001 of Singapore ("**SFA**").

To clarify, Dr Djeng's spouse, Dr Ko Siew Lan, and ODS have subscribed for their respective *pro rata* entitlements of Rights Shares with Warrants, as illustrated above, instead of renouncing the same in favour of Dr Djeng within the prescribed rights trading period as set out in the Offer Information Statement. For the avoidance of doubt, there is no change to the resultant shareholding interest of Dr Djeng, as he is deemed to have an interest in all the Rights Shares with Warrants held by his spouse, Dr Ko Siew Lan, and ODS under Section 7 of the Companies Act and Section 4 of the SFA.

Applicants with valid acceptances of their provisional allotments of Rights Shares with Warrants will be allocated in full for such acceptances.

2.2 Allotment of the Excess Rights Shares with Warrants

The provisional allotments of 91,614,348 Rights Shares with 91,614,348 Warrants which were not validly accepted or subscribed for by Entitled Shareholders, their renouncees and/or Purchasers under the Rights cum Warrants Issue (including entitlements to Rights Shares with Warrants which would have had accrued to Foreign Shareholders, if any, and fractional entitlements which were disregarded in arriving at the Entitled Shareholders' entitlements to the Rights Shares with Warrants), will be allotted to satisfy valid excess applications for the Rights Shares with Warrants.

In the allotment of any Excess Rights Shares with Warrants, preference has been given to the Entitled Shareholders for the rounding of odd lots. Directors and Substantial Shareholders (including the Undertaking Shareholders) who have control or influence over the Company in connection with the day-to-day affairs of the Company, or the terms of the Rights cum Warrants Issue, or have representation (direct or through a nominee) on the Board were ranked last in priority for the rounding of odd lots and allotment of the Excess Rights Shares with Warrants. The Company did not make any allotment and issuance of any Excess Rights Shares with Warrants that resulted in a transfer of controlling interest in the Company.

2.3 Allotment and crediting of the Rights Shares with Warrants

In the case of Entitled Scripholders and their renouncees with valid acceptances for the Rights Shares with Warrants and/or (if applicable) successful applications for the Excess Rights Shares with Warrants and who have, inter alia, failed to furnish or furnished incorrect or invalid Securities Account numbers in the relevant form comprised in the PAL, Share certificate(s) and Warrant certificate(s) representing such number of Rights Shares and Warrants, respectively, will be sent to such Entitled Scripholders by ordinary post, at their own risk, to their mailing addresses in Singapore as maintained with the Share Registrar within ten (10) Market Days after the Closing Date.

In the case of Entitled Depositors, Purchasers (whose registered addresses with CDP are within Singapore) and Entitled Scripholders and their renouncees (who have furnished valid Securities Account numbers in the relevant form comprised in the PAL) with valid acceptances for the Rights Shares with Warrants and/or (if applicable) successful applications for the Excess Rights Shares with Warrants, Share certificate(s) and Warrant certificate(s) representing such number of Rights Shares with Warrants, respectively, will be sent to CDP within ten (10) Market Days after the Closing Date and CDP will thereafter credit such number of Rights Shares with Warrants to their relevant Securities Accounts. CDP will then send a notification letter to the relevant subscribers, at their own risk, stating the number of Rights Shares and Warrants credited to their Securities Account.

2.4 Nil-Paid Rights in respect of Foreign Shareholders

No Nil-Paid Rights, which would otherwise have been provisionally allotted to Foreign Shareholders, have been sold “nil-paid” on the Catalist by the Company during the Rights Trading Period as provided in the Offer Information Statement. Accordingly, no net sale proceeds are available for distribution to Foreign Shareholders.

2.5 Net Proceeds from the Rights cum Warrants Issue

The Company has raised Net Proceeds of approximately S$14.94 million (after deducting estimated expenses of approximately S$0.33 million relating to the Rights cum Warrants Issue) from the Rights cum Warrants Issue. As disclosed in the Offer Information Statement, the Company intends to utilise the Net Proceeds to fund the working capital requirements of the Group, as follows:

Proposed use of Net Proceeds	Approximate Allocation of Net Proceeds (S$)	Approximate Allocation of Net Proceeds (%)
General working capital [(1)]	9,440,534	63.19
Repayment of loan from a Shareholder [(2)]	1,200,000	8.03
System maintenance and software upgrades	3,800,000	25.43
System revamp and CAPEX	500,000	3.35
Total	**14,940,534**	**100.00**

Notes:

(1) As the Company had received Prepayments from certain Undertaking Shareholders subsequent to the Company’s announcement dated 30 October 2025 in relation to the Rights cum Warrants Issue, the Company did not proceed to obtain short-term bridging loans. Accordingly, the Company will re-allocate the proposed use of Net Proceeds amounting to S$3,000,000 from repayment of short-term bridging loan to system maintenance and software upgrades. For completeness, the Prepayments amounting to S$3.90 million have been fully applied towards the Company’s working capital requirements, comprising mainly payroll expenses, and maintenance fees for medical equipment. Please refer to the Company’s announcements dated 13 February 2026 and 22 April 2026, and the Offer Information Statement, for further information in relation to the Prepayments.

(2) Please refer to paragraph 6 of Part 4 of the Offer Information Statement for further details in relation to the loan.

As and when the Warrants are exercised, the Exercise Proceeds raised will be applied towards business expansion and general working capital requirements of the Group (which includes administrative expenses, manpower costs, compliance costs, continuing listing expenses, professional fees and expenses to be incurred by the Group for exploring business opportunities) as set out in the table below, in the best interest of the Group.

For illustrative purposes only, assuming that the Rights cum Warrants Issue is fully subscribed, and all Warrants issued thereunder are exercised, the Company intends to use the Exercise Proceeds of approximately S$24,629,893 from the exercise of Warrants as follows:

Proposed use of Exercise Proceeds	**Approximate Allocation of Exercise Proceeds**	
	S$	**%**
Business expansion	14,777,936	60.00
General working capital	9,851,957	40.00
Total	**24,629,893**	**100.00**

The Company will make periodic announcements on the utilisation of the Net Proceeds and/or Exercise Proceeds as and when such proceeds are materially disbursed and provide a status report on the use of such proceeds in the interim and full-year financial statements issued pursuant to Rule 705 of the Catalist Rules and in the Company's annual report, until such time the proceeds have been fully utilised. Where the Net Proceeds and/or Exercise Proceeds have been used for working capital purposes, the Company will provide a breakdown with specific details on how the proceeds have been applied in the announcements and annual report. Where there is a material deviation in the use of Net Proceeds and/or Exercise Proceeds, the Company will announce the reasons for such deviation.

Pending the deployment of the Net Proceeds and/or Exercise Proceeds, such proceeds may be placed as deposits with financial institutions and/or invested in short-term money market or debt instruments and/or for any other purposes on a short-term basis, as the Directors may in their absolute discretion deem fit.

3. REFUND FOR INVALID OR UNSUCCESSFUL ACCEPTANCES AND EXCESS APPLICATIONS

When any of the acceptances of the Rights Shares with Warrants and/or (if applicable) application for the Excess Rights Shares with Warrants is invalid or unsuccessful in full or in part, the amount paid on acceptance and/or (if applicable) application, or the surplus application monies, as the case may be, will be returned or refunded to the relevant applicants by CDP on behalf of the Company without interest or any share of revenue or other benefit arising therefrom within three (3) business days after the commencement of trading of the Rights Shares with Warrants by any one or a combination of the following:

(i) where the acceptance and/or (if applicable) application had been made through CDP, by crediting the applicant's designated bank account via CDP's Direct Crediting Service or in the case where refunds are to be made to Depository Agents or Member Companies, by means of telegraphic transfer. In the event that an applicant is not subscribed to the CDP's Direct Crediting Service, any monies to be returned or refunded will be retained by CDP and credited to his Cash Ledger and subject to the same terms and conditions as Cash Distributions under CDP's "Operation of Securities Account with The Depository Terms and Conditions" (Cash Ledger and Cash Distributions as defined therein) (such retention by CDP being a good discharge of the Company's obligations);

(ii) where the acceptance and/or (if applicable) application had been made through Electronic Applications through an ATM of the Participating Bank or an Accepted Electronic Service, by crediting their bank accounts with the relevant banks, at their own risk, the receipt by such bank being a good discharge of the Company's and CDP's obligations, if any; or

(iii) where the acceptance and/or (if applicable) application had been made through the Share Registrar, by means of a crossed cheque drawn in Singapore currency on a bank in Singapore and sent to them at their mailing addresses as maintained with the Share Registrar by ordinary post at their own risk

Where any invalid or unsuccessful (whether in full or in part) acceptance and/or (if applicable) application had been made through CDP, the return or refund in accordance with the abovementioned paragraph (i) is expected to take place within three (3) business days after commencement of trading of the Rights Shares which is expected to take place on 26 June 2026.

4. ISSUANCE AND LISTING OF THE RIGHTS SHARES, WARRANTS AND WARRANT SHARES

The Company expects that the 492,597,856 Rights Shares and 492,597,856 Warrants will respectively be allotted and issued on or about 24 June 2026.

The 492,597,856 Rights Shares are expected to be listed and quoted on the Catalist with effect from 9.00 a.m. on 26 June 2026. The 492,597,856 Warrants are expected to be listed and quoted on the Catalist with effect from 9.00 a.m. on 29 June 2026. Further update announcement(s) on the listing of and quotation for the Rights Shares and the Warrants will be made by the Company when appropriate in due course.

As at the date of this announcement, the Company has been informed that there will be at least 100 warrantholders in the Company. Pursuant to the Catalist Rules, the SGX-ST requires a sufficient spread of holdings to provide for an orderly market in the Warrants. As a guide, the SGX-ST expects at least 100 warrantholders for a class of company warrants. Shareholders should note that in the event of an insufficient spread of holdings for the Warrants to provide for an orderly market in the trading of the Warrants, Warrantholders will not be able to trade their Warrants on Catalist.

The Warrant Shares arising from the exercise of the Warrants will, upon allotment and issue, be listed and quoted on the Catalist.

The Warrant Shares arising from the exercise of the Warrants will, upon allotment and issue, rank *pari passu* in all respects with the then existing issued Shares for any dividends, rights, allotments or other distributions, the record date for which falls on or after the date of issue of the Warrant Shares, save as may be otherwise provided in the Deed Poll.

The listing and quotation notice granted by the SGX-ST on 11 May 2026 for the dealing in and the listing of and quotation for (i) up to 492,597,856 Rights Shares to be issued by the Company, (ii) up to 492,597,856 Warrants to be issued by the Company, and (iii) up to 492,597,856 Warrant Shares to be issued by the Company upon the exercise of the Warrants, pursuant to the Rights cum Warrants Issue, on the Catalist of the SGX-ST, is not to be taken as an indication of the merits of the Rights cum Warrants Issue, the Rights Shares, the Warrants, the Warrant Shares, the Company, its subsidiaries and their securities.

5. CLARIFICATION ON EXPECTED TIMETABLE OF KEY EVENTS

As set out in paragraph 4 above, the 492,597,856 Rights Shares and 492,597,856 Warrants will respectively be allotted and issued on or about 24 June 2026, instead of 25 June 2026 as set out in the Offer Information Statement.

Accordingly, the Company wishes to update the indicative timetable for the remaining steps of the Rights cum Warrants Issue as follows (all references are to Singapore dates and times).

Expected date for issuance of Rights Shares	:	24 June 2026
Expected date for issuance of Warrants	:	24 June 2026
Expected date for crediting of Rights Shares with Warrants	:	26 June 2026
Expected date for refund of unsuccessful or invalid applications (if made through CDP)	:	26 June 2026
Expected date and time for the listing and commencement of trading of Rights Shares on the SGX-ST	:	26 June 2026 at 9.00 a.m.
Expected date and time for the listing and commencement of trading of Warrants on the SGX-ST (subject to there being an adequate spread of holdings of the Warrants to provide an orderly market in the trading of the Warrants)	:	29 June 2026 at 9.00 a.m.

Please note that the indicative timetable below is provided on the basis that the Rights Shares, Warrants and Warrant Shares will be listed and quoted on the Catalist. For the events listed which are described as "expected", please refer to future announcement(s) by the Company and/or the SGX-ST for the exact dates of these events.

Please note that if there is an insufficient spread of holdings for the Warrants to provide for an orderly market in the trading of the Warrants, the Warrants may not be listed and will be issued in registered form by way of Warrant Certificates and the Company will release further announcement(s) at the relevant time. In which case, the above indicative timetable may be amended and the Company will release further announcement(s) as may be appropriate. Where necessary, the Deed Poll may be amended without the consent of holders of the Warrants to address such scenario.

The Warrants may be exercised during the Exercise Period, being the period commencing on and including the date of issue of the Warrants and expiring at 5.00 p.m. on the date immediately preceding the expiry of 60 months from the date of issue of the Warrants, unless such date is a date on which the Register of Members and/or Register of Warrantholders of the Company is/are closed or is not a Market Day, in which event the Warrants shall expire on the date prior to the closure of the Register of Members and/or Register of Warrantholders of the Company or on the immediately preceding Market Day, as the case may be, but excluding such period(s) during which the Register of Members and/or Register of Warrantholders may be closed, subject to the terms and conditions of the Warrants as set out in the Deed Poll.

The Company shall, at least one (1) month before the expiry of the Exercise Period (the "**Expiry Date**") and on the Expiry Date, announce the expiry of the Exercise Period on the SGXNET, and arrange for a notice of expiry to be sent to all Warrantholders.

Please refer to the Offer Information Statement for further details in relation to the terms and conditions of the Warrants and the Deed Poll.

The Board would like to thank all Shareholders for their support for the Company by participating in the Rights cum Warrants Issue and enabling the successful completion of the Rights cum Warrants Issue.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
23 June 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.